Beyond F508del: equity as the next frontier in cystic fibrosis
Open Access
- 5 December 2025
- journal article
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 53, 101328
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Admixture’s impact on Brazilian population evolution and healthScience, 2025
- The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world studyThe Lancet Respiratory Medicine, 2024
- The clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) for people with CF without a F508del variant: A systematic review and meta-analysisJournal of Cystic Fibrosis, 2024
- Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescriptionEuropean Respiratory Journal, 2023
- Patient-derived cell models for personalized medicine approaches in cystic fibrosisJournal of Cystic Fibrosis, 2022